Can-Fite Obtains Patent For Treatment Of Osteoarthritis In Mammals

The company is considering possible partnerships with companies from the animal health pharmaceutical industry that could in-license and create Piclidenoson for the companion animal market. Canine osteoarthritis is being treated with oral non-steroidal anti-inflammatory drugs that only address symptoms and have damaging side effects, and an injectable disease modifying osteoarthritis drug which only affects the progression of the disease, according to the company. Click here to sign up for our daily insider newsletter.